Skip to main content
. Author manuscript; available in PMC: 2015 Apr 1.
Published in final edited form as: Breast Cancer Res Treat. 2014 Mar 2;144(3):591–597. doi: 10.1007/s10549-014-2891-0

Table 1. Patient characteristics.

Characteristic Median (range)
Age (in years) 45 (25–55)
Pre-chemotherapy AMH (in ng/mL) 0.11 (0.01–8.63)
N (%)
White race 106 (85 %)
Received bevacizumab 94 (76 %)
Used tamoxifen 64 (52 %)
12-month CRA 102/124 (82 %)
18-month CRA 81/100 (81 %)

CRA chemotherapy-related amenorrhea, AMH anti-mullerian hormone